Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Parsons

Showing results (811-820 of 821) with videos related to

Pageof 83
Sort By:
Cancer Research|November 10, 2022
ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy ResistanceMassimiliano Mellone, Klaudia Piotrowska, Giulia Venturi, et al.
Journal of the American Medical Informatics Association : JAMIA|August 28, 2001
A four-dimensional probabilistic atlas of the human brainJ Mazziotta, A Toga, A Evans, et al.
The Journal of Infectious Diseases|August 3, 2013
Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052)Jessica M Fogel, Lei Wang, Teresa L Parsons, et al.
Cell Reports. Medicine|June 22, 2022
Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblastsBenjamin P Sharpe, Annette Hayden, Antigoni Manousopoulou, et al.
Journal of Medicinal Chemistry|September 6, 2014
Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineeringThomas H Pillow, Janet Tien, Kathryn L Parsons-Reponte, et al.
Nature Biotechnology|January 24, 2012
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugatesBen-Quan Shen, Keyang Xu, Luna Liu, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 18, 2022
Tralesinidase Alfa Enzyme Replacement Therapy Prevents Disease Manifestations in a Canine Model of Mucopolysaccharidosis Type IIIBN Matthew Ellinwood, Bethann N Valentine, Andrew S Hess, et al.
JAMA Surgery|June 23, 2021
Risk Prediction Model of 90-Day Mortality After Esophagectomy for CancerXavier Benoit D'Journo, David Boulate, Alex Fourdrain, et al.
BMJ Open|November 22, 2019
Laparoscopically assisted versus open oesophagectomy for patients with oesophageal cancer-the Randomised Oesophagectomy: Minimally Invasive or Open (ROMIO) study: protocol for a randomised controlled trial (RCT)Rachel C Brierley, Daisy Gaunt, Chris Metcalfe, et al.
Genome Biology|April 17, 2021
A verified genomic reference sample for assessing performance of cancer panels detecting small variants of low allele frequencyWendell Jones, Binsheng Gong, Natalia Novoradovskaya, et al.
Pageof 83

Showing results (811-820 of 821) with videos related to

Sort By:
Pageof 83
Cancer Research|November 10, 2022
ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy ResistanceMassimiliano Mellone, Klaudia Piotrowska, Giulia Venturi, et al.
Journal of the American Medical Informatics Association : JAMIA|August 28, 2001
A four-dimensional probabilistic atlas of the human brainJ Mazziotta, A Toga, A Evans, et al.
The Journal of Infectious Diseases|August 3, 2013
Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052)Jessica M Fogel, Lei Wang, Teresa L Parsons, et al.
Cell Reports. Medicine|June 22, 2022
Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblastsBenjamin P Sharpe, Annette Hayden, Antigoni Manousopoulou, et al.
Journal of Medicinal Chemistry|September 6, 2014
Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineeringThomas H Pillow, Janet Tien, Kathryn L Parsons-Reponte, et al.
Nature Biotechnology|January 24, 2012
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugatesBen-Quan Shen, Keyang Xu, Luna Liu, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 18, 2022
Tralesinidase Alfa Enzyme Replacement Therapy Prevents Disease Manifestations in a Canine Model of Mucopolysaccharidosis Type IIIBN Matthew Ellinwood, Bethann N Valentine, Andrew S Hess, et al.
JAMA Surgery|June 23, 2021
Risk Prediction Model of 90-Day Mortality After Esophagectomy for CancerXavier Benoit D'Journo, David Boulate, Alex Fourdrain, et al.
BMJ Open|November 22, 2019
Laparoscopically assisted versus open oesophagectomy for patients with oesophageal cancer-the Randomised Oesophagectomy: Minimally Invasive or Open (ROMIO) study: protocol for a randomised controlled trial (RCT)Rachel C Brierley, Daisy Gaunt, Chris Metcalfe, et al.
Genome Biology|April 17, 2021
A verified genomic reference sample for assessing performance of cancer panels detecting small variants of low allele frequencyWendell Jones, Binsheng Gong, Natalia Novoradovskaya, et al.
Pageof 83